U.S. Markets closed

Aldeyra Therapeutics, Inc. (ALDX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.70-0.10 (-2.08%)
At close: 4:00PM EDT
People also watch
Full screen
Previous Close4.80
Bid4.50 x 100
Ask4.70 x 100
Day's Range4.60 - 4.85
52 Week Range3.80 - 8.19
Avg. Volume81,919
Market Cap71.12M
PE Ratio (TTM)-3.09
EPS (TTM)-1.52
Earnings DateAug 8, 2017 - Aug 14, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.20
Trade prices are not sourced from all markets
  • PR Newswire6 days ago

    Aldeyra Therapeutics Announces Last Patient Dosed in Dry Eye Disease Phase 2a Clinical Trial

    LEXINGTON, Mass., July 18, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to aldehydes, today announced that the last patient has completed dosing in Aldeyra's single-center, double-blind, randomized Phase 2a clinical trial of ADX-102 in Dry Eye Disease (DED). ADX-102 and other product candidates generated from Aldeyra's aldehyde trap platform sequester and facilitate the degradation of aldehydes, a class of endogenously generated pro-inflammatory mediators that are elevated in DED patients.

  • PR Newswirelast month

    Aldeyra Therapeutics to Present Novel Data on the Anti-Inflammatory Mechanism and Activity of ADX-102 at the World Congress on Inflammation 2017 Annual Meeting

    The poster presentation will highlight the differentiated effects of ADX-102 on inflammatory cell migration and activation, lung function, and biochemical mediators of inflammation in a mouse model of endotoxin-induced lung injury. ADX-102, a novel aldehyde sequestering agent, has been shown in animal models to reduce pro-inflammatory cytokines, decrease tissue edema in allergic and contact dermatitis, reduce healing time and fibrosis in radiation-induced mucositis, and diminish inflammatory pain.  In Phase 2 clinical trials in patients with noninfectious anterior uveitis and allergic conjunctivitis, two ocular inflammatory diseases, ADX-102 was statistically superior to control in reducing inflammation.

  • 24/7 Wall St.last month

    Aldeyra Stumbles Over Mid-Stage Clinical Results

    Aldeyra Therapeutics saw its shares slide on Wednesday after the company said its allergic conjunctivitis drug missed the primary endpoint in this Phase 2b trial.